ANTI-VEGF TREATMENT IN NEOVASCULAR AGE–RELATED MACULAR DEGENERATION

Ranibizumab and Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration

(2012) Daniel F. Martin et al.   OPHTHALMOLOGY

Ranibizumab versus Bevacizumab to Treat Neovascular Age-related Macular Degeneration

(2012) Usha Chakravarthy et al.   OPHTHALMOLOGY

Bevacizumab for Neovascular Age-Related Macular Degeneration Using a Treat-and-Extend Regimen: Clinical and Economic Impact

(2011) Gary Shienbaum et al.   AMERICAN JOURNAL OF OPHTHALMOLOGY

Myositis Ossificans

(2011) Deborah A. Martin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety and Efficacy of a Flexible Dosing Regimen of Ranibizumab in Neovascular Age-Related Macular Degeneration: The SUSTAIN Study

(2011) Frank G. Holz et al.   OPHTHALMOLOGY

A Treat and Extend Regimen Using Ranibizumab for Neovascular Age-Related Macular DegenerationClinical and Economic Impact

(2010) Omesh P. Gupta et al.   OPHTHALMOLOGY

Efficacy and Safety of Monthly versus Quarterly Ranibizumab Treatment in Neovascular Age-related Macular Degeneration: The EXCITE Study

(2010) Ursula Schmidt-Erfurth et al.   OPHTHALMOLOGY

INJECT AND EXTEND DOSING VERSUS DOSING AS NEEDED

(2010) Hassiba Oubraham et al.   RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES

A Variable-dosing Regimen with Intravitreal Ranibizumab for Neovascular Age-related Macular Degeneration: Year 2 of the PrONTO Study

(2009) Geeta A. Lalwani et al.   AMERICAN JOURNAL OF OPHTHALMOLOGY

Randomized, Double-Masked, Sham-Controlled Trial of Ranibizumab for Neovascular Age-related Macular Degeneration: PIER Study Year 1

(2008) Carl D. Regillo et al.   AMERICAN JOURNAL OF OPHTHALMOLOGY

Ranibizumab versus Verteporfin Photodynamic Therapy for Neovascular Age-Related Macular Degeneration: Two-Year Results of the ANCHOR Study

(2008) David M. Brown et al.   OPHTHALMOLOGY